HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib-Reference-Cited by-同舟云学术

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

Published:2019-03 Issue:3 Volume:30 Page:447-455
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Wang Y.,Jiang T.,Qin Z.,Jiang J.,Wang Q.,Yang S.,Rivard C.,Gao G.,Ng T.L.,Tu M.M.,Yu H.,Ji H.,Zhou C.,Ren S.,Zhang J.,Bunn P.,Doebele R.C.,Camidge D.R.,Hirsch F.R.

Funder

National Natural Science Foundation of China

Shanghai Education Development Foundation and Shanghai Municipal Education Commission

Science and Technology Commission of Shanghai Municipality

Development Fund for Shanghai Talents

University of Iowa Start-up Funds

American Cancer Society

Holden Comprehensive Cancer Center

The University of Iowa

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/3/447/28255113/mdy542.pdf

Reference31 articles.

1. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas;Shigematsu;Cancer Res,2005

2. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features;Buttitta;Int J Cancer,2006

3. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers;Tomizawa;Lung Cancer,2011

4. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas;Arcila;Clin Cancer Res,2012

5. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs;Kris;JAMA,2014

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment;Bioorganic Chemistry;2024-10

2. Recent advances in lung cancer organoid (tumoroid) research (Review);Experimental and Therapeutic Medicine;2024-08-01

3. SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study;Signal Transduction and Targeted Therapy;2024-07-15

4. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer;Cancer Cell;2024-07

5. Exploring tumor organoids for cancer treatment;APL Materials;2024-06-01